Yeon Hee Park, MD, PhD, on Metastatic Breast Cancer: Updated Survival Results of the Young-PEARL Study
2024 ASCO Annual Meeting
Yeon Hee Park, MD, PhD, of South Korea’s Samsung Medical Center and Sungkyunkwan University, discusses phase II findings on palbociclib plus exemestane with a GnRH agonist vs capecitabine in premenopausal patients with hormone receptor–positive, HER2-negative metastatic breast cancer (LBA1002).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
YoungPEARL study is a prospective randomized phase 2 study to compare palbociclib plus exemestane plus GnRH agonist versus capecitabine for premenopausal HR-positive HER2-negative metastatic breast cancers. Actually, this clinical trial was published and presented in 2019. According to that trial research, palbociclib plus exemestane plus GnRH antagonist showed a superior PFS compared to the capecitabine. Their median PFS was 20.1 months versus capecitabine, 14.4 months. This kind of real big research contributed to expansion of palbociclib plus AI label to include premenopausal population.
So now, here we reported updated overall survival research. Data cutoff is February 29th, 2024 with median follow-up duration of 54 months. So we follow up the updated PFS research to show the consistent superior PFS showed in palbociclib arm. Median PFS was 19.5 months versus 14 months of PFS shown in capecitabine arm. Hazard ratio in people was strongly enough to consider it's a big impact in terms of PFS.
And now, we show the overall survival research. There is no big difference between the two arm. Palbociclib arm showed the 54.7 months of PFS, and then capecitabine arm showed a remarkable PFS of 57.8 months. They did not show any difference, but it's 54 months of longer follow-up duration. Palbociclib arm showed a pretty consistent, longer overall survival of 54.8 months. So it's a really... Extended overall survival was shown in palbociclib arm. But palbociclib superior PFS did not lead to the overall survival benefit compare capecitabine arm. But capecitabine arm showed... Multivariate analysis showed the post-treatment CDK4/6 inhibitor was identified as a independent favorable factor for overall survival with statistical significance. So maybe post CDK inhibitor treatment contributed to extended overall survival in palbociclib arm.
The ASCO Post Staff
Efrat Dotan, MD, of Fox Chase Cancer Center, discusses results from the phase II EA2186 trial, the first prospective study aiming to define the optimal treatment approach for vulnerable older adults with newly diagnosed metastatic pancreatic cancer (Abstract 4003).
The ASCO Post Staff
Laurence Albiges, MD, PhD, of Gustave Roussy, Université Paris-Saclay, discusses phase III findings showing that high baseline serum KIM-1 levels were associated with poorer prognosis but improved clinical outcomes with atezolizumab vs placebo in patients with renal cell carcinoma at increased risk of recurrence after resection. Increased post-treatment KIM-1 levels were found to be associated with worse disease-free survival (Abstract 4506).
The ASCO Post Staff
Alicia Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Samuel R. Denmeade, MD, of Johns Hopkins University School of Medicine, discuss a study showing that patients with metastatic castration-resistant prostate whose disease is progressing on abiraterone with androgen-receptor alterations detected in the blood may benefit from bipolar androgen therapy. Routine liquid biopsy testing may enable further adoption of bipolar treatment (Abstract 5003).
The ASCO Post Staff
Alicia Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Susan Halabi, PhD, of the Duke Cancer Institute and Duke University School of Medicine, discuss a clinical-genetic model that identified novel circulating tumor DNA alterations that are prognostic of overall survival and may help to classify patients with metastatic castration-resistant prostate cancer into risk groups useful for selecting trial participants (Abstract 5007).
The ASCO Post Staff
Toni K. Choueiri, MD, FASCO, of the Dana-Farber Cancer Institute, discusses phase III findings showing that, in patients with advanced renal cell carcinoma (RCC), the benefit of lenvatinib plus pembrolizumab vs sunitinib in overall response rate does not appear to be affected by such factors as gene‐expression signatures for tumor‐induced proliferation, PD‐L1 status, or the mutation status of RCC driver genes.